

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Bio-medical Group Limited

遠生醫葯科技集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 140)

Financial adviser to China Bio-medical Group Limited



道亨證券有限公司

DaoHengSecurities Ltd.

COMPLETION OF SUBSCRIPTION AGREEMENT

The Directors are pleased to announce that completion of the Subscription Agreement took place on 30th September, 2004.

Trading of the Shares on the Stock Exchange has been suspended at the request of the Company with effect from 9:30 a.m. on 13th May, 2004. According to Rule 13.24 of the Listing Rules, an issuer shall carry out, directly or indirectly, a sufficient level of operations or have tangible assets of sufficient value and/or intangible assets for which a sufficient potential value can be demonstrated to the Stock Exchange to warrant the continued listing of the issuer's securities. In view of the Company's current financial position, the Company is required to submit to the Stock Exchange proposal that would enable it to demonstrate its compliance with Rule 13.24 of the Listing Rules. In this regard, trading of the Shares will remain suspended until further notice.

Reference is made to the joint announcements of the Company and Hong Jin Holdings Limited (the "Subscriber") dated 7th September, 2004 and 22nd July, 2004 respectively and the circular to the Shareholders dated 12th August, 2004 (the "Circular") issued by the Company and the Subscriber regarding, among other things, the Subscription Agreement.

Defined terms used in this announcement shall have the same meanings as those defined in the Circular.

COMPLETION OF SUBSCRIPTION AGREEMENT

The Directors are pleased to announce that all conditions to the Subscription Agreement have been satisfied or waived in accordance with the terms of the Subscription Agreement and completion of the Subscription Agreement took place on 30th September, 2004.

SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structures of the Company are as follows:

	Immediately before completion of the Subscription Agreement		Immediately after completion of the Subscription Agreement	
	(Shares)	(%)	(Shares)	(%)
The Subscriber	–	–	643,835,616	67.5
Yuan Yun Nan	21,892,000	7.1	21,892,000	2.3
Other public Shareholders	288,179,347	92.9	288,179,347	30.2
Total	<u>310,071,347</u>	<u>100.0</u>	<u>953,906,963</u>	<u>100.0</u>

As at the date of this announcement, the Board comprises two Executive Directors, namely Dr. Wan Kwong Kee and Mr. Chan Peng Kuan and three independent non-executive Directors, namely Mr. Zhou Haijun, Mr. Ng Wai Hung and Mr. Xu Zhi.

Trading of the Shares on the Stock Exchange has been suspended at the request of the Company with effect from 9:30 a.m. on 13th May, 2004. According to Rule 13.24 of the Listing Rules, an issuer shall carry out, directly or indirectly, a sufficient level of operations or have tangible assets of sufficient value and/or intangible assets for which a sufficient potential value can be demonstrated to the Stock Exchange to warrant the continued listing of the issuer's securities. In view of the Company's current financial position, the Company is required to submit to the Stock Exchange proposal that would enable it to demonstrate its compliance with Rule 13.24 of the Listing Rules. In this regard, trading of the Shares will remain suspended until further notice.

By order of the Board
China Bio-medical Group Limited
Wan Kwong Kee
Chairman

Hong Kong, 30th September, 2004

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.

Please also refer to the published version of this announcement in China Daily.